<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 27, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6263933/antibody-lectin-chimeras-ablec-clinical?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=pqvt8z&amp;utm_campaign=2339218+-+Antibody+Lectin+Chimeras+(AbLec)+Global+Market+Report+2026%3a+Insights+on+Clinical+Innovation%2c+Technology+Platforms%2c+Development+Trends+%26+Clinical+Opportunities&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Antibody Lectin Chimeras (AbLec) Clinical Innovation, Technology Platform, Development Trends &amp; Clinical Opportunity Insights 2026">"Antibody Lectin Chimeras (AbLec) Clinical Innovation, Technology Platform, Development Trends &amp; Clinical Opportunity Insights 2026"</a> has been added to ResearchAndMarkets.com's offering. Key findings and highlights: <ul><li>Comprehensive analysis of the glyco-immunology landscape</li><li>Assessment of glyco-immune checkpoints in cancer immunotherapy</li><li>Evaluation of next-generation glycan-targeting therapies</li><li>In-depth review of the antibody-lectin chimera (AbLec) technology platform</li><li>Analysis of molecular design, mechanisms of action and target selection strategies</li><li>Coverage of current research, development trends and future opportunities</li><li>Review of market drivers, development challenges and growth potential</li><li>Competitive profiling of leading innovators and related platform technologies</li></ul> Why Antibody-Lectin Chimeras Matter and Why This Report Is Essential Antibody-lectin chimeras represent an emerging and highly specialized area within cancer immunotherapy and glyco-oncology. Unlike established immune checkpoint inhibitors directed at protein-mediated pathways such as PD-1/PD-L1 and CTLA-4, AbLec technology is designed to target glyco-immune checkpoints by combining tumor-specific monoclonal antibodies with carbohydrate-binding lectin domains. This strategy addresses glycan-mediated immune suppression, an increasingly important mechanism of tumor immune escape identified through advances in cancer glycobiology. Although the antibody-lectin chimera platform remains at an early stage of development, it is supported by a strong scientific rationale. Research originating at Stanford University has demonstrated the potential to block glycan-mediated immunosuppressive pathways at the tumor-immune cell interface while maintaining antibody-directed tumor targeting. Preclinical findings have reported enhanced antibody-dependent cellular phagocytosis, increased natural killer cell-mediated cytotoxicity and improved antitumor activity compared with conventional monoclonal antibodies. No AbLec candidates are publicly known to have entered clinical development, positioning the platform as a preclinical but potentially differentiated opportunity within next-generation oncology therapeutics. This report assesses the scientific, technical, translational and commercial prospects of antibody-lectin chimeras, including the biological rationale for glyco-immune checkpoint targeting, current research activity, intellectual property considerations, development barriers and long-term market potential. Scientific and Translational Insights Covered in the Report The report examines altered tumor glycosylation and the role of glyco-immune checkpoints in cancer progression, immune evasion and treatment resistance. It also reviews the evolution of glycan-directed therapeutics, including anti-glycan antibodies, glycan-editing approaches, lectins, glycan-degrading enzymes, decoy receptors and antibody-lectin chimera platforms. Detailed coverage is provided across AbLec molecular architecture, mechanism of action, tumor antigen selection, lectin selection and available evidence supporting platform feasibility. The analysis also considers protein engineering requirements, pharmacological optimization, potential safety concerns, manufacturability, preclinical validation and the translational pathway required before clinical testing. The modular nature of antibody-lectin chimeras may support the development of constructs targeting different tumor antigens and immunosuppressive glycans. The report evaluates this flexibility alongside the platform's potential compatibility with established and emerging immunotherapies, including checkpoint inhibitors, therapeutic antibodies and other immune-modulating treatment strategies. Organizations Advancing AbLec Research and Development The antibody-lectin chimera competitive landscape remains highly concentrated because of the platform's early development status. Stanford University originated the underlying technology and conducted foundational research involving the conjugation of tumor-targeting antibodies with lectin domains for glyco-immune checkpoint blockade. Commercial activity is also at an initial stage. Valora Therapeutics is currently the primary company publicly associated with commercialization of the platform through a licensing agreement with Stanford University. Beyond this technology transfer activity, no publicly disclosed AbLec clinical programs or direct industrial competitors have been identified. This limited competitive field highlights both the novelty of the technology and the substantial scientific and development risks associated with an emerging therapeutic modality. Future Outlook for the Antibody-Lectin Chimera Market Antibody-lectin chimeras could contribute to a new generation of cancer immunotherapies capable of addressing glyco-immune checkpoints alongside established protein-based checkpoint pathways. Continued progress in glycobiology, structural biology, protein engineering and antibody development may enable more selective AbLec constructs targeting diverse tumor antigens, glycan signatures and immune-suppressive mechanisms. Future advancement will depend on molecular design optimization, target validation, safety assessment, scalable manufacturing, robust preclinical studies and eventual clinical confirmation of therapeutic benefit. Key challenges include lectin specificity, off-target binding, immunogenicity, pharmacokinetics, tumor penetration and the selection of responsive patient populations. Despite the absence of clinical-stage candidates and the limited number of commercial participants, growing interest in glyco-immunology supports the long-term potential of antibody-lectin chimera technology. By integrating scientific evidence, platform biology, competitive intelligence, intellectual property analysis, development trends and market opportunity assessment, this 2026 report provides a focused overview of AbLec clinical innovation and its potential role in the future cancer immunotherapy landscape. Key Topics Covered 1. Research Methodology 2. Introduction To Glyco-Immunology 2.1 Cancer Glycobiology 2.2 Glyco-Immune Checkpoints 2.3 Limitations Of Current Immune Checkpoint Inhibitors 3. Why Glyco-Immune Checkpoints Matter 4. Evolution of Glycan-Targeting Therapeutics 4.1 Anti-Glycan Antibodies 4.2 Glycan Editing Approaches 4.3 Lectin-Based Therapeutics 4.4 Glycan-Degrading Enzymes 4.5 Decoy Receptors 4.6 Positioning Of Antibody-Lectin Chimeras 5. Antibody-Lectin Chimera (AbLec) Platform 5.1 Platform Overview 5.2 Molecular Design 5.3 Mechanism Of Action 5.4 Patent Landscape 5.5 Target Selection Strategy 5.6 Advantages Over Existing Modalities 5.7 Potential Challenges 6. Current &amp; Future Development Landscape 6.1 Current Evidence &amp; Development Status 6.2 Future Development Opportunities 7. Antibody-Lectin Chimera Market Dynamics 7.1 Drivers &amp; Opportunities 7.2 Challenges &amp; Development Risks 8. Competitive Landscape 8.1 Valora Therapeutics 8.1.1 Company Overview 8.1.2 Platform Technology List of Figures Figure 2-1: Cancer Glycobiology: From Normal Glycosylation To Malignant Transformation Figure 2-2: Biological Consequences Of Aberrant Glycosylation Figure 2-3: Major Cancer-Associated Glycan Alterations Figure 2-4: Glycans Promote Cancer Progression Figure 2-5: Cancer Glycobiology Leads To Glyco-Immunology Figure 2-6: Impact Of Siglec Activation On Innate Immunity Figure 2-7: Glyco-Immune Checkpoints Regulate Adaptive Immunity Figure 2-8: Major Limitations Of Current Immune Checkpoint Inhibitors Figure 2-9: Why Many Patients Do Not Respond To Immune Checkpoint Inhibitors Figure 2-10: Mechanisms Of Primary &amp; Acquired Resistance Figure 2-11: Emergence Of Alternative Immune Checkpoints Figure 2-12: Immune-Related Adverse Events Following Checkpoint Blockade Figure 3-1: Why Glyco-Immune Checkpoints Matter In Cancer Figure 3-2: Glyco-Immune Checkpoints Connect Multiple Hallmarks Of Cancer Figure 4-1: Development Of Anti-Glycan Antibodies In Cancer Therapy Figure 4-2: Clinical Success Of GD2-Targeted Therapy Figure 4-3: Limitations Of Anti-Glycan Antibodies Figure 4-4: Why Anti-Glycan Antibodies Are Not Sufficient Figure 4-5: Major Glycan Editing Strategies Figure 4-6: Challenges Of Glycan Editing Figure 4-7: Mechanisms Of Lectin-Based Therapeutics Figure 4-8: Challenges Of Lectin Based Therapeutics Figure 4-9: Engineering Strategies For Lectin Therapeutics Figure 4-10: Evolution Of Lectin-Based Therapeutics Figure 4-11: Catalytic Advantage Of Glycan-Degrading Enzymes Figure 4-12: Mechanism Of Glycan Degrading Enzymes Figure 4-13: Biological Effects Of Desialylation Figure 4-14: Challenges of Glycan-Degrading Enzyme Therapy Figure 4-15: Siglec-Fc Decoy Receptor Structure Figure 4-16: Therapeutic Actions Of Siglec Decoy Receptors Figure 4-17: Decoy Receptors v/s Conventional Checkpoint Blockade Figure 4-18: Limitations Of Soluble Decoy Receptors Figure 4-19: Evolution Toward Antibody-Lectin Chimeras Figure 4-20: Immunological Effects Of AbLecs Figure 5-1: Therapeutic Workflow Of AbLec Platform Figure 5-2: Position Of AbLecs Within The Cancer-Immunity Cycle Figure 5-3: Engineering Strategy For Constructing An Antibody-Lectin Chimera Figure 5-4: Affinity v/s Avidity In AbLec Design Figure 5-5: Sequential Mechanism Of Action Of Antibody-Lectin Chimeras Figure 5-6: Cellular Consequences Of Glyco-Immune Checkpoint Blockade Figure 5-7: Workflow For Selecting An AbLec Therapeutic Target Figure 5-8: Factors Influencing Target Selection Figure 5-9: Key Advantages Of AbLecs Over Existing Glycan-Targeting Modalities Figure 5-10: Major Scientific, Biological &amp; Translational Challenges Associated With AbLec Development Figure 6-1: Future Development Opportunities For AbLec Platform Figure 7-1: Major Market Drivers Supporting Development &amp; Commercialization Of AbLecs Figure 7-2: Key Market Challenges Affecting Clinical Translation &amp; Commercialization Of AbLecs Figure 8-1: Antibody-Lectin Chimera - General Molecular Structure List of Tables Table 2-1: Major Glyco Immune Checkpoint Pathways Table 2-2: Major Limitations Of Current Immune Checkpoint Inhibitors Table 4-1: Glycan Editing v/s Anti-Glycan Antibodies Table 4-2: Major Glycan-Degrading Enzymes Relevant To Cancer Therapy Table 4-3: Evolution Of Glycan-Targeting Therapeutics Table 4-4: Comparison Of Major Glycan-Targeting Modalities Table 5-1: Design Principles Of AbLec Platform Table 5-2: Key Characteristics Of An Ideal AbLec Platform Table 5-3: Therapeutic Objectives Of AbLec Platform Table 5-4: Immune Cells Influenced by AbLec Therapy Table 5-5: Key Features Of AbLec Patent Portfolio Table 5-6: Examples Of Potential Antibody-Lectin Pairings For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6263933/antibody-lectin-chimeras-ablec-clinical?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=pqvt8z&amp;utm_campaign=2339218+-+Antibody+Lectin+Chimeras+(AbLec)+Global+Market+Report+2026%3a+Insights+on+Clinical+Innovation%2c+Technology+Platforms%2c+Development+Trends+%26+Clinical+Opportunities&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/6n7cjr</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/OGJkMGFjZGEtYmE4Yi00OWFhLWFjYjgtNGYxMzQ5Yjg5ZmUyLTEwMjY3MzctMjAyNi0wOC0yNy1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Antibody Lectin Chimeras (AbLec) Global Market Report 2026: Insights on Clinical Innovation, Technology Platforms, Development Trends & Clinical Opportunities

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn